BridgeMD
New treatment option for Pancreatic Cancer
Official title Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer
ClinicalTrials.gov ID: NCT03498326
What this study is testing
What is Gemcitabine?
Gemcitabine is an investigational medicine, being studied as a potential treatment for pancreatic cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The prognosis of pancreatic cancer is extremely poor, even in those patients who had underwent surgery, the 5-year survival is still less than 10%. Current guidelines recommend Gemcitabine monotherapy for R0 resection of pancreatic cancer.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 90
You may be able to join if
- 18 years old and above.
- Surgery for R0 resection.
- The gemcitabine chemotherapy regimen was not previously used for the treatment of other malignancies.
- Eastern Cooperative Oncology Group score 0-2 points.
- Blood routine: The neutrophil count is at least 1.5\ 10\^9/ml, and the platelet count is at least 100\ 10\^9/ml.Hemoglobin is at least 80g/L.
You likely can't join if
- Endocrine carcinoma, acinar pancreatic carcinoma, or cystadenocarcinoma (cystadenocarcinoma).
- Surgery for pancreatic cancer fails to reach the R0 resection criteria.
- Pancreatic cancer received radiotherapy before surgery.
- Malignant brain metastases.
- There are other serious cancer history.
- Active infection, severe diarrhea.
See the full eligibility criteria
- 18 years old and above.
- Surgery for R0 resection.
- The gemcitabine chemotherapy regimen was not previously used for the treatment of other malignancies.
- Eastern Cooperative Oncology Group score 0-2 points.
- Blood routine: The neutrophil count is at least 1.5\ 10\^9/ml, and the platelet count is at least 100\ 10\^9/ml.Hemoglobin is at least 80g/L.
- Liver function: bilirubin does not exceed 1.5 times the upper limit of normal; alanine aminotransferase and aspartate aminotransferase does not exceed the upper limit of normal 3 times; kidney function: creatinine ≤ 1.2...
- Endocrine carcinoma, acinar pancreatic carcinoma, or cystadenocarcinoma (cystadenocarcinoma).
- Surgery for pancreatic cancer fails to reach the R0 resection criteria.
- Pancreatic cancer received radiotherapy before surgery.
- Malignant brain metastases.
- There are other serious cancer history.
- Active infection, severe diarrhea.
- Others: Those who are allergic to celecoxib; or who are intolerant to celecoxib, require continuous aspirin or Non-steroidal anti-inflammatory drugs; similar chemical or biological components and sulfa drugs that...
The study team makes the final eligibility decision.
Where it's taking place
- Hangzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 90 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hangzhou, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.